ATE486078T1 - 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors - Google Patents

5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors

Info

Publication number
ATE486078T1
ATE486078T1 AT06785619T AT06785619T ATE486078T1 AT E486078 T1 ATE486078 T1 AT E486078T1 AT 06785619 T AT06785619 T AT 06785619T AT 06785619 T AT06785619 T AT 06785619T AT E486078 T1 ATE486078 T1 AT E486078T1
Authority
AT
Austria
Prior art keywords
oxadiazolopyrazine
thiadiazolopyrazine
disubstituted
ligands
chemokine receptor
Prior art date
Application number
AT06785619T
Other languages
English (en)
Inventor
Biju Purakkattle
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE486078T1 publication Critical patent/ATE486078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
AT06785619T 2005-06-29 2006-06-27 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors ATE486078T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69516205P 2005-06-29 2005-06-29
PCT/US2006/024908 WO2007005403A1 (en) 2005-06-29 2006-06-27 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands

Publications (1)

Publication Number Publication Date
ATE486078T1 true ATE486078T1 (de) 2010-11-15

Family

ID=37137404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785619T ATE486078T1 (de) 2005-06-29 2006-06-27 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors

Country Status (10)

Country Link
US (1) US7897606B2 (de)
EP (1) EP1907399B1 (de)
JP (1) JP2009500328A (de)
CN (1) CN101253180B (de)
AT (1) ATE486078T1 (de)
CA (1) CA2613428A1 (de)
DE (1) DE602006017849D1 (de)
ES (1) ES2353401T3 (de)
MX (1) MX2008000367A (de)
WO (1) WO2007005403A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070011475A (ko) * 2004-05-12 2007-01-24 쉐링 코포레이션 Ｃｘｃｒ1 및 ｃｘｃｒ2 케모카인 길항제
CA2613607A1 (en) * 2005-06-29 2007-01-04 Schering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
ES2784223T3 (es) 2012-06-20 2020-09-23 Univ Virginia Patent Foundation Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina
WO2023159248A1 (en) * 2022-02-21 2023-08-24 The Regents Of The University Of Colorado A Body Corporate Re-sensitizing multidrug-resistant (mdr) gram-negative bacteria to colistin using ionophores
WO2023192935A1 (en) * 2022-03-30 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment for inflammation and fibrosis in retinal neovascular diseases

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB988704A (en) * 1961-03-11 1965-04-07 Ishikawajima Harima Heavy Ind Nitride bearing ductile steel
US3115496A (en) * 1963-05-13 1963-12-24 Upjohn Co Certain 3, 4-disubstituted-1, 2, 5-thiadiazole-1, 1-dioxides and their preparation
DE1669798A1 (de) 1966-07-28 1971-08-26 Huels Chemische Werke Ag Verfahren zum Stabilisieren markomolekularer Polyacetale
CS214745B2 (en) 1976-08-28 1982-05-28 Huels Chemische Werke Ag Shaped and non-shaped products from plastic materials
NL189197C (nl) 1979-09-04 1993-02-01 Bristol Myers Squibb Co 3,4-digesubstitueerde-1,2,5-thiadiazool-1-oxiden en 1,1-dioxiden, bereiding daarvan alsmede farmaceutische preparaten.
EP0040696B1 (de) 1980-04-30 1986-08-27 Merck & Co. Inc. Aminothiadiazole als gastrische Inhibitoren
US4394508A (en) * 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
US4510309A (en) * 1981-03-03 1985-04-09 Bristol-Myers Company Histamine H2 -antagonists
IE53068B1 (en) 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
DK317283A (da) 1982-07-08 1984-01-09 Glaxo Group Ltd Fremgangsmaade til fremstilling af thiadiazolderivater
FI832519L (fi) 1982-07-12 1984-01-13 Bristol Myers Co Farmaceutiska foerfaranden och sammansaettningar
AU2222083A (en) * 1982-12-14 1984-06-21 Smith Kline & French Laboratories Limited Pyridine derivatives
US4863936A (en) * 1982-12-14 1989-09-05 Smith Kline & French Laboratories Limited 3,5-Substituted-2-pyridyl-alkylaminocyclobutenediones having histamine h1 -antagonist activity
DE3374007D1 (en) * 1982-12-23 1987-11-12 Smith Kline French Lab Pyridine derivatives
DE3309655A1 (de) 1983-03-17 1984-09-20 Bayer Ag, 5090 Leverkusen 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4497810A (en) * 1983-10-14 1985-02-05 Merck & Co., Inc. Thiatriazine dioxides as gastric anti-secretory agents
US4562184A (en) * 1984-04-02 1985-12-31 Merck & Co., Inc. Substituted-aminohydroxypropoxy-thiadiazoles, β-blocking compositions and use
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
GB8501535D0 (en) * 1985-01-22 1985-02-20 Smith Kline French Lab Chemical compounds
HU198696B (en) 1987-01-20 1989-11-28 Nissan Chemical Ind Ltd Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
JPH02256668A (ja) 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
US5206252A (en) 1992-05-08 1993-04-27 American Home Products Corporation Thiadiazolyl-amino derivatives of benzopyrans and indanes
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5466712A (en) 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
DK0796243T3 (da) 1994-11-16 1999-09-13 American Home Prod Diaminocyclobuten-3,4-dioner
US5494925A (en) * 1994-12-02 1996-02-27 Sterling Winthrop Inc. 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TR199901710T2 (xx) 1997-01-23 1999-09-21 Smithkline Beecham Corporation IL-8 resept�r antagonistleri.
WO1998033763A1 (en) 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AR015425A1 (es) 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
DE69903053T2 (de) 1998-10-02 2003-05-22 Neurosearch As Ballerup Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
ATE284387T1 (de) 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
US6376555B1 (en) 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
WO2000035855A1 (en) 1998-12-14 2000-06-22 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
AU761407B2 (en) 1998-12-16 2003-06-05 Bayer Aktiengesellschaft New biphenyl and biphenyl-analogous compounds as integrin antagonists
US6420396B1 (en) 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
EP1220840A2 (de) 1999-10-15 2002-07-10 Bristol-Myers Squibb Pharma Company Bicyclische und tricyclische amine als modulatoren der aktivität von chemokin rezeptoren
JP2003512349A (ja) 1999-10-15 2003-04-02 デュポン ファーマシューティカルズ カンパニー ケモカイン受容体活性のモジュレーターとしてのベンジルシクロアルキルアミン
EP1265905A4 (de) 2000-03-01 2003-03-12 Smithkline Beecham Corp Il-2 receptor antagonisten
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
EP1274415A4 (de) 2000-03-14 2005-09-07 Smithkline Beecham Corp Il-8 rezeptorantagonisten
AU2001240021A1 (en) 2000-04-13 2001-10-30 Millennium Pharmaceuticals, Inc. Diazafluorenone il-8 receptor antagonists
CN1454204A (zh) 2000-05-30 2003-11-05 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
AU2002217970A1 (en) * 2000-11-28 2002-06-11 Curis, Inc. Wnt signalling assay, methods and uses thereof
DE60230722D1 (de) 2001-01-16 2009-02-26 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
ATE346043T1 (de) 2001-01-16 2006-12-15 Smithkline Beecham Corp Il-8-rezeptorantagonisten
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
AU2002303084B2 (en) 2001-02-02 2006-05-25 Pharmacopiea, Inc. 3,4-di-substituted cyclobutene-1, 2 -diones as CXC chemokine receptor antagonists
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
DK1818325T3 (da) * 2001-04-16 2010-05-31 Schering Corp 3,4-di-substituerede cyklobuten-1,2-dioner som CXC-chemokin receptorligander
MXPA04003439A (es) 2001-10-12 2004-07-08 Schering Corp Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
MXPA04009127A (es) 2002-03-18 2005-01-25 Schering Corp Tratamiento de enfermedades mediadas por quimiocinas.
AU2003288922A1 (en) 2002-10-09 2004-05-04 Pharmacopeia, Inc. Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
WO2005051974A2 (en) 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
EP1529531A1 (de) 2003-11-04 2005-05-11 4Sc Ag Oxadiazolopyrazin-Derivate als pharmazeutisch aktive Wirkstoffe
WO2005044270A1 (en) * 2003-11-04 2005-05-19 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
US7671212B2 (en) 2003-12-22 2010-03-02 Schering Corporation Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
US20090131445A1 (en) * 2004-10-14 2009-05-21 Compass Pharmaceuticals Llc Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents
CA2613607A1 (en) 2005-06-29 2007-01-04 Schering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands

Also Published As

Publication number Publication date
CN101253180A (zh) 2008-08-27
ES2353401T3 (es) 2011-03-01
DE602006017849D1 (de) 2010-12-09
JP2009500328A (ja) 2009-01-08
US7897606B2 (en) 2011-03-01
US20070015731A1 (en) 2007-01-18
CN101253180B (zh) 2011-08-03
EP1907399B1 (de) 2010-10-27
CA2613428A1 (en) 2007-01-11
WO2007005403A1 (en) 2007-01-11
MX2008000367A (es) 2008-03-07
EP1907399A1 (de) 2008-04-09

Similar Documents

Publication Publication Date Title
SE0202241D0 (sv) Novel Compounds
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
TW200510301A (en) Novel compounds
SE0302232D0 (sv) Novel Compounds
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
TW200745056A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
EA200401194A1 (ru) Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
GEP20104962B (en) Fused heterocyclic compounds
MY139941A (en) Indole derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
MY153719A (en) Prokineticin 1 receptor antagonists
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
TW200716566A (en) Prokineticin 2 receptor antagonists
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties